: To analyze differences in demographic pattern and hospitalization outcomes in post-traumatic stress disorder (PTSD) with opioid use disorder (OUD) patients managed with versus without behavioral therapy (BT). : We conducted case-control study using Nationwide Inpatient Sample and identified PTSD and OUD using ICD⁻9⁻CM codes. Linear regression model was used to evaluate impact of BT on inpatient stay and cost. : We analyzed 1531 inpatient admissions and 786 patients received BT. Females had higher odds of receiving BT during inpatient management for PTSD with OUD (OR 1.210; 95% CI 1.020⁻1.436). About 63.1% patients receiving BT were benefited by Medicaid. Patients receiving BT had an increase in hospital stay by 1.27 days (P = 0.085) and hospitalization cost by $4734 (P = 0.018). There were no transfers to short term hospitals and lower transfers to skilled nursing facility (3.8% vs. 10.1%) in patients receiving BT. : This study aims to reinforce combination management with psychotropic medications and BT in PTSD patients with comorbid OUD during hospitalization as it significantly decreases adverse disposition of the patient and thereby improves the quality of life post-treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115830 | PMC |
http://dx.doi.org/10.3390/bs8080073 | DOI Listing |
S Afr J Surg
December 2024
Department of Biostatistics, Faculty of Health Sciences, University of the Free State, South Africa.
Background: Postoperative patients' risk for developing venous thromboembolism (VTE) can be predicted using the adapted Caprini risk assessment model which informs administration of postoperative VTE prophylaxis. The study aimed to assess the appropriateness of postoperative VTE prophylaxis of patients according to the adapted Caprini scores and investigate whether a patient's HIV status influenced postoperative VTE prophylaxis administration.
Methods: This cohort study included patients who had elective or urgent surgery at a tertiary hospital, Bloemfontein.
Curr Drug Saf
January 2025
National Center Chalbi Belkahia of Pharmacovigilance, Department of Collection and Analysis of Adverse Effects, Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine, Research unit: UR17ES12, Tunis, Tunisia.
Background: Trimethoprim-Sulfamethoxazole (TMP-SMX) is a commonly used antibiotic for the treatment of several infections, such as urinary tract infections, respiratory infections, and in certain cases, septic arthritis. Rhabdomyolysis (RM) is very rare and less than 20 cases have been reported, so far, in the literature, in particular in immunocompromised patients. Here, we report a case of TMP-SMX-induced RM in an immunocompetent patient, adding to the limited data on this association.
View Article and Find Full Text PDFCurr Neurovasc Res
January 2025
Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Objective: The concept of "time is brain" is crucial for the reperfusion therapy of ischemic stroke. However, the Infarct Growth Rate (IGR) varies among individuals, which is regarded as a more powerful factor than the time when determining infarct volume and its association with clinical outcomes. For stroke patients with a similar infarct volume, a longer time from stroke Onset to Imaging (OTI) correlates with a lower IGR, which may indicate a better prognosis.
View Article and Find Full Text PDFCardiovasc Hematol Disord Drug Targets
January 2025
Division of Pulmonary and Critical Care Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Background: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy with systemic tissue-- type-plasminogen-activator (tPA) based on risk assessment. Currently, AC is the standard of care for most patients with intermediate-high-risk PE, with low-dose tPA emerging as an effective alternative.
View Article and Find Full Text PDFJ Psychopharmacol
January 2025
Department of Psychiatry, McGill University, Montreal, QC, Canada.
Background: Switching between versions of medication products happens commonly despite challenges in achieving bioequivalence and therapeutic equivalence. Central nervous system and psychiatric drugs, especially those that are technically demanding to manufacture and have complex pharmacokinetic properties, such as long-acting injectables (LAIs), pose particular challenges to bioequivalence and safe and efficacious drug switching.
Aims: To assess whether drugs deemed "bioequivalent" are truly interchangeable in drug switching.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!